Trial Profile
Phase II Non-Randomized Three Arm Trial of Induction Chemotherapy With Nab-Paclitaxel and Cisplatin (AP: Arms 1 and 3) or Single Agent Nab-paclitaxel (A: Arm 2) as Induction Therapy Followed by Definitive Concurrent Chemoradiation for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (HNSCC): "The APA Trial"
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 28 Apr 2023
Price :
$35
*
At a glance
- Drugs Cisplatin (Primary) ; Paclitaxel (Primary) ; Cetuximab
- Indications Head and neck cancer; Hypopharyngeal cancer; Laryngeal cancer; Oropharyngeal cancer; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms The APA Trial
- Sponsors Celgene Corporation
- 25 Apr 2023 Planned End Date changed from 12 Dec 2029 to 12 Dec 2024.
- 18 Jun 2020 Planned End Date changed from 31 Oct 2030 to 12 Dec 2029.
- 18 Jun 2020 Status changed from recruiting to active, no longer recruiting.